Next-generation sequencing (NGS) based applications have proven to be disruptive within the clinic as well as in research. In contrast to conventional diagnostic tests, a single NGS test can identify thousands of genetic variants at once. The frequent, and still increasing, usage of NGS- based applications, resulted in the generation of mass data volumes.
Understanding how the genome is transcribed in different cell types and what changes occur when cells undergo a biological or chemical treatment leads to better insights into biology, the underpinnings of a particular disease, and possibly the success of a specific drug treatment.
Partnering with Bluebee, brings Lexogen closer to its “seamless end-to-end” approach to extract meaning from all RNA data in a smooth regimen often comprised of discrete steps involving resources that previously have not been accessible to all researchers.
Bluebee’s unique cloud-based accelerated genomics analysis platform combines best-in-class tools with a high-performance computational engine to enable efficient processing and fast, affordable diagnostics for hospitals, research centers and other clients.
The German Cancer Research Center (DKFZ) in Heidelberg, Germany is one of the largest data analysis centres in the International Cancer Genome Consortium (ICGC). DKFZ takes on the challenge of sequencing tumour samples to find mutated regions in the patient’s cancer genomes which can be targeted more efficiently with available drugs.
Sign up for our newsletter
Our latest news, publications and developments delivered to your inbox